MedTrace Logo

Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study

NCT06573853 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 428

Last updated 2024-10-24

No results posted yet for this study

Summary

The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is:

Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA.

1. Recieved PFA or RFA 1 year ago
2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings
3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT

Conditions

  • Paroxysmal Supraventricular Tachycardia
  • Catheter Ablation

Interventions

PROCEDURE

Focal Pulsed Field Ablation (PFA)

Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.

PROCEDURE

Focal Radiofrequecy Ablation (RFA)

Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.

Sponsors & Collaborators

  • Shanghai MicroPort EP MedTech Co., Ltd.

    collaborator INDUSTRY

  • Caijie Shen

    lead OTHER

Principal Investigators

  • Caijie Shen · First Affiliated Hospital of Ningbo University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06573853 on ClinicalTrials.gov